Navigation Links
New Shared Synthetic Replikin Cancer Vaccines
Date:1/22/2013

BOSTON, Jan. 22, 2013 /PRNewswire/ -- Replikins Ltd. and Brain Research Associates announced today that specific conserved genomic Replikin peptide sequences for the first time have been found to be shared among different histological cancer types, permitting the seven day synthesis of new shared cancer vaccines.

(Photo: http://photos.prnewswire.com/prnh/20130122/PH45996 )

Each of the shared Replikins was found to be present in multiple malignancies. The genomic Replikin®Count (number of Replikin genomic structures per 100 amino acids) relates quantitatively to the five year human mortality rate for each cancer type, the first genomic structures found to be so related (1) (see Figure). The lowest genomic Replikin®Counts were found in those cancers which have the lowest five year mortality rates, as in prostate and thyroid cancer; and the highest Replikin®Counts were found in glioblastoma multiforme, pancreatic and lung cancer, which have the highest mortality rates.

Genomic Replikins in cancer are quantitatively predictive of mortality rate, as recently also found by Replikins Ltd. in viral infectious disease (1-10), and these Replikin structures enable the production of effective specific synthetic vaccines in seven days (9,10). These genomic Replikins in cancer are also the basis of aids for cancer diagnosis, as the Antimalignin Antibody in Serum (AMAS)®Test, the anti-Replikin antibody test, which was shown to be elevated in all common cancers (1). This test has proved useful in helping to distinguish benign from malignant growths, when the cancer is small and barely detected by radiographic techniques, eg. as an aid in diagnosing cancer early in lung and in breast lesions (1). The AMAS®Test can now also be used as a marker to track cancer prevention by synthetic Replikins vaccines (9,10) in high risk subjects, and to track efficacy of treatment by synthetic Replikins blockers (10). 

Contact:
Anne Borsanyi
aborsanyi@replikins.com
646-320-5910
http://www.replikins.com/

References:

1. Bogoch S and Bogoch ES. Genome Replikin CountTM  Predicts Increased Lethality of Cancer. Nature Precedings doi:10.1038/npre.2012.7143.1

2. Bogoch, S. and Bogoch, E.S. Genome Replikin CountTM Predicts Increased Infectivity/Lethality of Viruses. Nature Precedings npre2012.7144. 04April 2012. 


3. Bogoch, S. and Bogoch, E.S. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins. Nature Precedings doi:10.1038/npre.2011.6279.1.23Aug 2011. 


4. Bogoch,S. and Bogoch, ES. Bogoch Replikins Pandemic Prevention: Increase of Strain-Specific Influenza Genomic Replikin Counts, Having Predicted Outbreaks and their Location Seven Times Consecutively, Up to Two Years in Advance, Provides Time for Prevention of Pandemics. Nature Precedings.doi:10.1038/npre.2012.6952.1 01 March, 2012 


5. Bogoch, S. and Bogoch, E.S. Marked Rise in Replikin Counts in H5N1 Influenza Virus Localized to Lethality Gene pB1.Nature Precedings doi:10.1038/npre.2011.6420.1

6. Bogoch S, Bogoch ES.   Replikins Pandemic Prevention: Increase of Strain-Specific Influenza Genomic Replikin Counts, Having Predicted Outbreaks and their Location Seven Times Consecutively, Up to Two Years in Advance, Provides Time for Prevention of Pandemics.  Nature Precedings doi:10.1038/npre.2012.6952.1                                                                       

7. Report #49. Replikins Press<replikins.com>.Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer, June 19, 2012

8. Report #42,  Replikins Press<replikins.com>. UN Food and Agriculture Organization (FAO) discussion of Replikins, DVM Newsmagazine, (Sept. 8, 2011).

9. Jackwood, MW et al. Efficacy of a Replikin Peptide Vaccine against Low Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53(4): 613‐617, 2009

10. Report # 17. Replikins Press<replikins.com>.Replikins Oral Vaccine Synthesized in 7 days protects 91% of Shrimp Against Lethal Virus . March 11, 2008.

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Synthetic Biologics Reports Third Quarter 2012 Financial Results
3. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
4. Taming mavericks: Stanford researchers use synthetic magnetism to control light
5. Synthetic Biologics Completes $10.8 Million Private Placement Financing
6. Synthetic Biologics Announces $10.8 Million Financing
7. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
8. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
9. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
10. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
11. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... October 10, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the BoxWorks conference in San Francisco. , The presentation, “Automating GxP ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
Breaking Biology Technology:
(Date:8/23/2017)...  The general public,s help is being enlisted in what,s thought to ... and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest ... the gut. The project's goal is to help advance scientific knowledge of ... ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
Breaking Biology News(10 mins):